

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

U-118MG

RRID:CVCL_0633

Type: Cell Line

Proper Citation

RRID:CVCL_0633

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0633

Proper Citation: RRID:CVCL_0633

Description: Cell line U-118MG is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Astrocytoma

Defining Citation: [PMID:327080](#), [PMID:450131](#), [PMID:833871](#), [PMID:2253244](#), [PMID:2454731](#), [PMID:3518877](#), [PMID:3675803](#), [PMID:4134536](#), [PMID:4312117](#), [PMID:4313504](#), [PMID:4337530](#), [PMID:4369403](#), [PMID:6220172](#), [PMID:6260907](#), [PMID:7017212](#), [PMID:7459858](#), [PMID:9220028](#), [PMID:10402232](#), [PMID:10416987](#), [PMID:10560660](#), [PMID:11414198](#), [PMID:16697959](#), [PMID:19365568](#), [PMID:19435942](#), [PMID:20143388](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:22570425](#), [PMID:27397505](#), [PMID:27582061](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Shown to be a U-138MG derivative (PubMed=20143388)..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: U-118MG

Synonyms: U-118 MG, U-118-MG, U118-MG, U118MG, U118, 118 MG, 118MG

Cross References: BTO:BTO_0004605, CLO:CLO_0009451, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-7712, ATCC:HTB-15, BioGRID_ORCS_Cell_line:445, BioSample:SAMN03151974, BioSample:SAMN03472723, BioSample:SAMN10988042, cancercellines:CVCL_0633, CCRID:3101HUMTCHu216, Cell_Model_Passport:SIDM01193, ChEMBL-Cells:ChEMBL3308793, ChEMBL-Targets:ChEMBL1075602, CLS:300362, Cosmic:687588, Cosmic:849852, Cosmic:849878, Cosmic:920817, Cosmic:1175822, Cosmic:1217672, Cosmic:1571919, Cosmic:1610738, Cosmic:2301554, Cosmic:2367553, Cosmic:2550362, Cosmic:2668299, Cosmic:2701084, Cosmic-CLP:687588, DepMap:ACH-000040, EGA:EGAS00001000978, GDSC:687588, GEO:GSM101671, GEO:GSM101672, GEO:GSM888812, GEO:GSM1374968, GEO:GSM1374969, GEO:GSM1670554, IARC_TP53:4195, KCB:KCB 2013002YJ, LiGeA:CCLE_075, LINCS_LDP:LCL-1358, PharmacDB:U118MG_1616_2019, PRIDE:PXD030304, Progenetix:CVCL_0633, PubChem_Cell_line:CVCL_0633, Wikidata:Q54973503

ID: CVCL_0633

Hierarchy: cvcl_0020

Record Creation Time: 20220427T221639+0000

Record Last Update: 20260905T182613+0000

Ratings and Alerts

No rating or validation information has been found for U-118MG.

Warning: Problematic cell line: Contaminated. Shown to be a U-138MG derivative (PubMed=20143388).

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00350.

Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Shown to be a U-138MG derivative (PubMed=20143388).. **Warning:** Discontinued: ATCC; CRL-7712

Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Shown to be a U-138MG derivative (PubMed=20143388)..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1987 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang Z, et al. (2026) Machine learning model on multi-omics data enables risk stratification and identifies molecular heterogeneity and therapeutic targets in glioblastoma. *Molecular cancer*, 25(1).

Zhang L, et al. (2026) ZBTB7B inhibits glioma tumorigenicity by upregulating GPR17 and CXCL10. *Journal of molecular cell biology*, 17(11).

Song J, et al. (2026) JOSD1 Deubiquitinates Twist1 and Facilitates Epithelial-Mesenchymal Transition in Glioblastoma. *Cell biochemistry and function*, 44(4), e70208.

Sidhu RS, et al. (2026) Rap1b promotes glioma growth and stemness via regulation of Notch1 and VEGFR2 signaling pathways. *Cellular signalling*, 143, 112457.

Chen K, et al. (2026) Amino acid supplementation enhances in vivo efficacy of lipid nanoparticle-mediated mRNA delivery in preclinical models. *Science translational medicine*, 18(840), eadx4097.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Cornelissen FMG, et al. (2025) Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype. *Molecular cancer therapeutics*, 24(12), 1878.

Lv P, et al. (2025) Glioma-Associated Mesenchymal Stromal/Stem Cells Derived Exosomal miR-191 Promotes the Proneural-to-Mesenchymal Transition in Glioblastoma Cells via PTEN/PI3K/AKT Signaling. *International journal of nanomedicine*, 20, 8811.

Daskou M, et al. (2025) Phosphatidylserine receptors TIM-1 and AXL mediate tick-borne Powassan virus entry. *iScience*, 28(12), 113930.

Tang M, et al. (2024) Inhibition of thioredoxin reductase 1 sensitizes glucose-starved glioblastoma cells to disulfidptosis. *Cell death and differentiation*.

Zhong Y, et al. (2024) Vasorin Exocytosed from Glioma Cells Facilitates Angiogenesis via VEGFR2/AKT Signaling Pathway. *Molecular cancer research : MCR*, 22(7), 668.

Denisova OV, et al. (2023) PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells. *Molecular oncology*, 17(9), 1803.

Feng Y, et al. (2023) Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. *Cell reports*, 42(12), 113503.

Thomas D, et al. (2023) Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability. *Cancer discovery*, 13(2), 496.

Sun K, et al. (2023) Oncolytic Viral Therapy for Glioma by Recombinant Sindbis Virus. *Cancers*, 15(19).

Xu J, et al. (2023) Identifying the personalized driver gene sets maximally contributing to abnormality of transcriptome phenotype in glioblastoma multiforme individuals. *Molecular oncology*, 17(11), 2472.

Grunst MW, et al. (2023) Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein. *PLoS pathogens*, 19(5), e1011407.

Ding S, et al. (2023) Piperidine CD4-Mimetic Compounds Expose Vulnerable Env Epitopes Sensitizing HIV-1-Infected Cells to ADCC. *Viruses*, 15(5).

Perrett HR, et al. (2023) Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies. *Cell reports*, 42(5), 112524.

Kwon YD, et al. (2023) Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain. *mAbs*, 15(1), 2223350.